FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283738863> ?p ?o ?g. }

• W4283738863 abstract "Abstract Study question What does the evolution of luteinizing hormone (LH) throughout the follicular phase look like in different treatment protocols for ovarian stimulation in IVF/ICSI? Summary answer Evolution of LH during the follicular phase of ovarian stimulation differs between Gonadotropin-Releasing Hormone (GnRH) analogues, with a significant decrease of LH in antagonist cycles. What is known already Physicians aim to tailor ovarian stimulation protocols to the patient, with protocols varying in type of GnRH analogue and gonadotropin. However, there is no clear consensus on the best treatment protocol and especially the role of LH is still not completely understood as earlier studies focused mainly on suppressing LH levels. Literature has since indicated that excessively suppressed LH levels could be detrimental for clinical outcomes. Research on LH is hampered by multiple measurements during the cycle, different treatment schedules and patients switching schedules over time. Study design, size, duration This was a non-interventional, retrospective, observational cohort study. 2200 ovarian stimulation cycles for assisted reproduction were analyzed, in 1303 individual patients. Patients were treated during the period of January 1st 2015 until September 30th 2020. Cycles were included if the patient was between 18 and 43 years of age, stimulated with human menopausal gonadotropin (hMG) or recombinant follicle stimulating hormone (rec-FSH, follitropin α or β) and using GnRH analogues. Participants/materials, setting, methods Data were extracted from two databases used at a tertiary infertility clinic. Cycles were divided into six treatment protocols: GnRH antagonist/hMG (13.8%), antagonist/rec-FSH (19.7%), long agonist/hMG (35.7%), long agonist/rec-FSH (4.8%), short agonist/hMG (22.5%) and short agonist/rec-FSH (3.5%). 59.5% of cycles were pretreated with an oral contraceptive pill (OCP). LH evolution was visualized by plotting LH levels against the days of the follicular phase and repeated daily LH measures were fitted with a linear mixed model. Main results and the role of chance Basal LH was significantly lower in antagonist/hMG cycles pretreated with OCP compared to no pretreatment (estimated difference -1.23 IU/L, p &lt; 0.001). Mean LH value throughout the follicular phase was significantly lower with OCP pretreatment in antagonist/hMG (estimated difference -1.05 IU/L, p &lt; 0.001) and antagonist/rec-FSH cycles (estimated difference -0.52 IU/L, p &lt; 0.001). When LH evolution throughout the follicular phase was analyzed, no significantly different evolution between cycles with and without OCP was detected (all p &gt; 0.1). Hence further analysis of the LH profiles was performed in the six protocol groups making no distinction between OCP use or not. LH evolution was significantly different between all six protocol groups (p &lt; 0.001). In antagonist/hMG cycles, LH values showed a significant decrease of 0.17 IU/L per day (p &lt; 0.001). In antagonist/rec-FSH cycles, the decrease per day was 0.26 IU/L (p &lt; 0.001).The decrease in LH was significantly larger in rec-FSH cycles than hMG (estimated difference 0.09 IU/L per day, p &lt; 0.001). Short agonist/hMG cycles showed a significant increase in LH of 0.04 IU/L per day (p = 0.002), while the increase of 0.01 IU/L per day in rec-FSH cycles was not significant (p = 1.00). In long agonist cycles, no significant in- or decrease in LH values during the follicular phase was found (p = 1.00). Limitations, reasons for caution Stimulation protocols were chosen by the treating physician which is a limitation of the retrospective design. The authors were able to partly respond to this limitation by adjusting for age and using different cycles per patient in all mixed models. Wider implications of the findings Using profiles to show LH evolution allowed the visualization of the decrease in the evolution of LH in antagonist cycles, even more pronounced in cycles stimulated with rec-FSH compared to hMG. This decrease in LH and the potential impact on estradiol levels and follicle growth needs further examination. Trial registration number not applicable" @default.
• W4283738863 created "2022-07-02" @default.
• W4283738863 creator A5072850484 @default.
• W4283738863 creator A5090535991 @default.
• W4283738863 creator A5091014703 @default.
• W4283738863 date "2022-06-29" @default.
• W4283738863 modified "2023-09-26" @default.
• W4283738863 title "P-668 The LH endocrine profile in Gonadotropin-Releasing Hormone analogue cycles" @default.
• W4283738863 doi "https://doi.org/10.1093/humrep/deac107.617" @default.
• W4283738863 hasPublicationYear "2022" @default.
• W4283738863 type Work @default.
• W4283738863 citedByCount "0" @default.
• W4283738863 crossrefType "journal-article" @default.
• W4283738863 hasAuthorship W4283738863A5072850484 @default.
• W4283738863 hasAuthorship W4283738863A5090535991 @default.
• W4283738863 hasAuthorship W4283738863A5091014703 @default.
• W4283738863 hasConcept C126322002 @default.
• W4283738863 hasConcept C134018914 @default.
• W4283738863 hasConcept C187785154 @default.
• W4283738863 hasConcept C2777688143 @default.
• W4283738863 hasConcept C2777702977 @default.
• W4283738863 hasConcept C2777886879 @default.
• W4283738863 hasConcept C2778575703 @default.
• W4283738863 hasConcept C2778782382 @default.
• W4283738863 hasConcept C2778894405 @default.
• W4283738863 hasConcept C2779192864 @default.
• W4283738863 hasConcept C2779234561 @default.
• W4283738863 hasConcept C2779279165 @default.
• W4283738863 hasConcept C2781230225 @default.
• W4283738863 hasConcept C46699223 @default.
• W4283738863 hasConcept C54355233 @default.
• W4283738863 hasConcept C71315377 @default.
• W4283738863 hasConcept C71924100 @default.
• W4283738863 hasConcept C86803240 @default.
• W4283738863 hasConceptScore W4283738863C126322002 @default.
• W4283738863 hasConceptScore W4283738863C134018914 @default.
• W4283738863 hasConceptScore W4283738863C187785154 @default.
• W4283738863 hasConceptScore W4283738863C2777688143 @default.
• W4283738863 hasConceptScore W4283738863C2777702977 @default.
• W4283738863 hasConceptScore W4283738863C2777886879 @default.
• W4283738863 hasConceptScore W4283738863C2778575703 @default.
• W4283738863 hasConceptScore W4283738863C2778782382 @default.
• W4283738863 hasConceptScore W4283738863C2778894405 @default.
• W4283738863 hasConceptScore W4283738863C2779192864 @default.
• W4283738863 hasConceptScore W4283738863C2779234561 @default.
• W4283738863 hasConceptScore W4283738863C2779279165 @default.
• W4283738863 hasConceptScore W4283738863C2781230225 @default.
• W4283738863 hasConceptScore W4283738863C46699223 @default.
• W4283738863 hasConceptScore W4283738863C54355233 @default.
• W4283738863 hasConceptScore W4283738863C71315377 @default.
• W4283738863 hasConceptScore W4283738863C71924100 @default.
• W4283738863 hasConceptScore W4283738863C86803240 @default.
• W4283738863 hasIssue "Supplement_1" @default.
• W4283738863 hasLocation W42837388631 @default.
• W4283738863 hasOpenAccess W4283738863 @default.
• W4283738863 hasPrimaryLocation W42837388631 @default.
• W4283738863 hasRelatedWork W1965086880 @default.
• W4283738863 hasRelatedWork W1969085914 @default.
• W4283738863 hasRelatedWork W1981134796 @default.
• W4283738863 hasRelatedWork W2015670268 @default.
• W4283738863 hasRelatedWork W2021860704 @default.
• W4283738863 hasRelatedWork W2090128259 @default.
• W4283738863 hasRelatedWork W2170775580 @default.
• W4283738863 hasRelatedWork W2434309838 @default.
• W4283738863 hasRelatedWork W4283738863 @default.
• W4283738863 hasRelatedWork W2286857689 @default.
• W4283738863 hasVolume "37" @default.
• W4283738863 isParatext "false" @default.
• W4283738863 isRetracted "false" @default.
• W4283738863 workType "article" @default.